Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection

Journal of Controlled Release(2024)10.1016/j.jconrel.2024.05.008Source: DataRank Database

A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection is a research paper published in Journal of Controlled Release (2024). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.68)OA: hybridTopics (50)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Mariah E. Nelson,Daria Andriyanova,Renata B. Filler ORCID,Arya Ökten ORCID,Olivia Q. Antao ORCID

Live enrichment

PubMed:38734312 PMC:PMC11665867 OpenAlex:https://openalex.org/W4396842209

NIAMS NIH HHS

Grant: R01 AR073912

NIA NIH HHS

Grant: P30 AG068635

NIGMS NIH HHS

Grant: T32 GM136651

NHLBI NIH HHS

Grant: F30 HL149151

FWCI

1.68

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.jconrel.2024.05.008

publisherhttps://doi.org/10.1016/j.jconrel.2024.05.008

publisherhttps://api.elsevier.com/content/article/PII:S0168365924002931?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0168365924002931?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38734312

Fields of Study

Immunotherapy and Immune ResponsesSARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchAnimalsSpike Glycoprotein, CoronavirusImmunity, HumoralCOVID-19 VaccinesMiceCOVID-19PorosityFemaleAntibodies, NeutralizingAntibodies, ViralBiocompatible MaterialsMice, Inbred BALB CB-LymphocytesSARS-CoV-2Influenza VaccinesMice, Inbred C57BLOrthomyxoviridae Infections

MeSH Terms

COVID-19SARS-CoV-2COVID-19 VaccinesAnimalsAntibodies, ViralB-LymphocytesBiocompatible MaterialsFemaleInfluenza VaccinesMice, Inbred BALB CMice, Inbred C57BLOrthomyxoviridae InfectionsPorosityMiceImmunity, HumoralAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

ImmunityMicroporous materialBiomaterialVirologyAntibodyImmunologyMedicineImmune systemChemistryBiomedical engineeringsustained releaseVaccine PlatformAntigen Delivery Platform

Sustainable Development Goals

SDG 0: Good health and well-being